A Six-month, Open-label, Multi-center Study of the Safety and Efficacy of PRC-063 in Adults and Adolescents With ADHD
Phase of Trial: Phase III
Latest Information Update: 13 Jul 2015
Price : $35 *
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Registrational
- Sponsors Rhodes Pharmaceuticals
- 13 Jul 2015 Status changed from active, no longer recruiting to completed.
- 06 Nov 2014 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov record.
- 25 Jun 2014 New trial record